I'm sure they did have high hopes and perhaps being more cautious after 2013. Still a decent chance in Ph3 for superior (up to 12wks) dosing. Worst case I expect is non inferior in efficacy and dosing and comparable inflammation rates. That of course would make it a "me too" kind of a drug. We'll know in two years...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.